Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06666725 · ClinicalTrials.gov registry record · NA
Effect of Added-sugar Menu Labels
A NA study, sponsored by University of California, Davis.
- Completed
- Registry status
- NA
- Development phase
- 11,275
- Enrollment target
NCT06666725: Completed NA study, sponsored by University of California, Davis.
NCT06666725 is a NA study that has completed, run by University of California, Davis. The registered enrollment target is 11,275 participants, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (704% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06666725, a NA study, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- NA
- Development phase
- 11,275 participants
- Enrollment target
Study Summary
To compare two added-sugar menu label--(1) red, icon-only, 150% of the menu text height and (2) black, icon-plus-text, 100% of the menu text height--to a no-label control on grams of added sugar ordered using two different added-sugar labeling thresholds: (1) ≥50% of Daily Value for added sugar (equivalent to ≥25g) and (2) ≥100% of Daily Value for added sugar (equivalent to ≥50g)
Primary Outcome
Continuous variable. Average grams of added sugar in foods and beverages selected, averaged across fast-food and full-service menus, analyzed using linear regression to examine differences between factor levels
Interventions
- OTHER Menu label
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11,275 participants |
| Start Date | 2024-12-23 |
| Est. Completion | 2025-02-13 |
| Phase | NA |
What the finished NCT06666725 record still lists
NCT06666725 is an interventional study that assigns participants to a tested intervention. Its 11,275 participants enrollment target places it among the larger protocols in the corpus, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (704% higher).
The record links to 0 conditions, and to 1 intervention - of which Menu label is the first listed.
NCT06666725 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06666725 about?
NCT06666725 is a clinical study titled "Effect of Added-sugar Menu Labels". To compare two added-sugar menu label--(1) red, icon-only, 150% of the menu text height and (2) black, icon-plus-text, 100% of the menu text height--to a no-label control on grams of added sugar ordered using two different added-sugar labeling thresholds: (1) ≥50% of Daily Value for added sugar (equ...
What is the current status of trial NCT06666725?
This trial is currently completed. It is a NA study. The enrollment target is 11,275 participants. The study started on 2024-12-23. Estimated completion is 2025-02-13.
What interventions are being tested in trial NCT06666725?
The interventions under investigation include: Menu label (OTHER).
Who is sponsoring clinical trial NCT06666725?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06666725's enrollment target sits among peer trials
11,275 14th of 2000 higher than 1,987 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06677060 · 11,300 participants · Phase 3
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
- NCT06531824 · 11,000 participants · Phase 3
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
- NCT07136012 · 11,000 participants · Phase 3
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
- NCT07181109 · 11,000 participants · Phase 3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI